Advertisement
Screener

XERIS BIOPHARMA HOLDINGS, INC. (XERS) Pre-Tax Income

2.4 / 5 stars · 31/64 Roast Me

XERIS BIOPHARMA HOLDINGS, INC. Pre-Tax Income

XERIS BIOPHARMA HOLDINGS, INC. (XERS) reported Pre-Tax Income of $554.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.

Financial Statements › Income Statement › Pre-tax Income

us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest · last filed 2026-03-02

  • XERIS BIOPHARMA HOLDINGS, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2025 was $554.00K.
  • XERIS BIOPHARMA HOLDINGS, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2024 was -$57.10M.
  • XERIS BIOPHARMA HOLDINGS, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2023 was -$63.50M.
  • XERIS BIOPHARMA HOLDINGS, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2022 was -$96.08M.
Period endIncome (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 12 month
2025-12-31$554.00K
10-K · filed 2026-03-02
2024-12-31-$57.10M
10-K · filed 2026-03-02
2023-12-31-$63.50M
10-K · filed 2026-03-02
2022-12-31-$96.08M
10-K · filed 2025-03-06
2021-12-31-$122.72M
10-K · filed 2024-03-06

Similar stocks

Stock NameCountryMarket CapPE Ratio
Stoke Therapeutics, Inc. (STOK)United States$1.630B-9.82
Rapport Therapeutics, Inc. (RAPP)United States$1.623B-14.56
Syndax Pharmaceuticals Inc (SNDX)United States$1.606B-8.82
Eton Pharmaceuticals, Inc. (ETON)United States$1.701B80.74
Kailera Therapeutics, Inc. (KLRA)United States$1.552B
ANAPTYSBIO, INC (ANAB)United States$1.546B-60.20
Innoviva, Inc. (INVA)United States$1.493B4.62
Xencor Inc (XNCR)United States$1.776B-7.33
ArriVent BioPharma, Inc. (AVBP)United States$1.485B-10.25
Septerna, Inc. (SEPN)United States$1.783B-63.01